2,2-dimethyl-4-[(4-methylphenoxy)methyl]-1,3-dioxolane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,2-dimethyl-4-[(4-methylphenoxy)methyl]-1,3-dioxolane
• 化学式: C₁₃H₁₈O₃
• 分子量: 222.284
• InChiKey: DNHKWAFAFVWTQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-4-[(4-methylphenoxy)methyl]-1,3-dioxolane 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 生成 3-(4-甲基苯氧基)-1,2-丙烷二醇
  参考文献：
  名称：

  Naphthyloxy acetic acid derivatives and a pharmaceutical composition comprising them as an active ingredient

  摘要：

  式(I)的萘氧乙酸衍生物 其中A为H，-(烷基)COOR1，-(烷基)CONR2R3，-(烷基)OH，-(烷基)四唑，-(烷基)CN；E为单键或烷基；G为—S—，—SO—，—SO2—，—O—或—NR4—；L为烷基，—(CH2)m—CH═CH—(CH2)n—或—(CH2)x—CH(OH)—(CH2)y—；M为苯基，苯基(硫、氧、氨基)，二苯甲基，二苯甲基(硫、氧、氨基)，以及包含它们作为活性成分的药物组合物。式(I)的化合物可以结合PGE2受体，并表现出对PGE2受体的拮抗或激动活性。因此，它们可用作抗高脂血症、预防流产、镇痛剂、止泻药、催眠剂、利尿剂、抗糖尿病药、引产剂、泻药、抗溃疡药、抗胃炎药或降压药等。

  公开号：

  US06335366B2
• 作为产物：
  描述：

  对甲酚 、 2,2-二甲基-1,3-二氧环戊基-4-甲醇对甲基苯磺酸酯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 2,2-dimethyl-4-[(4-methylphenoxy)methyl]-1,3-dioxolane
  参考文献：
  名称：

  Naphthyloxy acetic acid derivatives and a pharmaceutical composition comprising them as an active ingredient

  摘要：

  式(I)的萘氧乙酸衍生物 其中A为H，-(烷基)COOR1，-(烷基)CONR2R3，-(烷基)OH，-(烷基)四唑，-(烷基)CN；E为单键或烷基；G为—S—，—SO—，—SO2—，—O—或—NR4—；L为烷基，—(CH2)m—CH═CH—(CH2)n—或—(CH2)x—CH(OH)—(CH2)y—；M为苯基，苯基(硫、氧、氨基)，二苯甲基，二苯甲基(硫、氧、氨基)，以及包含它们作为活性成分的药物组合物。式(I)的化合物可以结合PGE2受体，并表现出对PGE2受体的拮抗或激动活性。因此，它们可用作抗高脂血症、预防流产、镇痛剂、止泻药、催眠剂、利尿剂、抗糖尿病药、引产剂、泻药、抗溃疡药、抗胃炎药或降压药等。

  公开号：

  US06335366B2

文献信息

• TETRACYCLIC COMPOUND
  申请人：Kinoshita Kazutomo

  公开号：US20120083488A1

  公开（公告）日：2012-04-05

  A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).

  一种由下面的一般式（I）表示的化合物，或其盐或溶剂化物，可用作ALK抑制剂，对于伴有ALK异常的疾病的预防或治疗是有用的，例如癌症、癌症转移、抑郁症或认知功能障碍（方程式中包含的符号的含义如规范中所述）。
• OXIME ESTER
  申请人：Nishimae Yuichi

  公开号：US20130188270A1

  公开（公告）日：2013-07-25

  Compounds of the formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 for example independently of each other are hydro-gen, C 1 -C 20 alkyl, (II), COR 16 or NO 2 , provided that at least one pair of R 1 and R 2 , R 2 and R 3 , R 3 and R 4 , R 5 and R 6 , R 6 and R 7 , or R 7 and R 8 is (III); R 9 , R 10 , R 11 and R 12 for example independently of each other are hydrogen, C 1 -C 20 alkyl which optionally substituted; or R 9 , R 10 , R 11 , and R 12 independently of each other are unsubstituted or substituted phenyl; X is CO or a direct bond; R 13 is for example C 1 -C 20 alkyl which optionally is substituted, C 2 -C 12 alkenyl, C 4 -C 8 cycloalkenyl, C 2 -C 12 alkinyl, C 3 -C 10 -cycloalkyl, phenyl or naphthyl both of which are optionally substituted; R 14 is for example hydrogen, C 3 -C 8 cycloalkyl, C 2 -C 5 alkenyl, C 1 -C 20 alkoxy, C 1 -C 20 alkyl, phenyl or naphthyl; R 15 is for example C 6 -C 20 aryl or C 5 -C 20 heteroaryl; R 16 is for example C 6 -C 20 aryl which is unsubstituted or substituted by one or more C 1 -C 20 alkoxy or C 1 -C 20 alkyl; are in particular suitable as photoinitiators for color filter applications.

  式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7和R8，例如独立地是氢、C1-C20烷基、(II)、COR16或NO2，条件是至少有一对R1和R2、R2和R3、R3和R4、R5和R6、R6和R7或R7和R8是(III)；R9、R10、R11和R12，例如独立地是氢、C1-C20烷基，可选择地被取代；或者R9、R10、R11和R12独立地是未取代或取代的苯基；X是CO或直接键；R13，例如C1-C20烷基，可选择地被取代，C2-C12烯基，C4-C8环烯基，C2-C12炔基，C3-C10环烷基，苯基或者萘基，两者可选择地被取代；R14，例如氢，C3-C8环烷基，C2-C5烯基，C1-C20烷氧基，C1-C20烷基，苯基或者萘基；R15，例如C6-C20芳基或C5-C20杂芳基；R16，例如C6-C20芳基，未取代或被一个或多个C1-C20烷氧基或C1-C20烷基取代；特别适用于彩色滤光片应用的光引发剂。
• [EN] OXIME ESTER DERIVATIVES OF BENZOCARBAZOLE COMPOUNDS AND THEIR USE AS PHOTOINITIATORS IN PHOTOPOLYMERIZABLE COMPOSITIONS<br/>[FR] DÉRIVÉS ESTER D'OXIME DE BENZOCARBAZOLES ET LEUR UTILISATION COMME PHOTOINITIATEURS DANS DES COMPOSITIONS PHOTOPOLYMÉRISABLES
  申请人：BASF SE

  公开号：WO2012045736A1

  公开（公告）日：2012-04-12

  Compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and R8 for example independently of each other are hydro- gen, C1-C20alkyl, (II), COR16 or NO2, provided that at least one pair of R1 and R2, R2 and R3, R3 and R4, R5 and R6, R6 and R7, or R7 and R8 is (III); R9, R10, R11 and R12 for example independently of each other are hydrogen, C1-C20alkyl which optionally substituted; or R9, R10, R11, and R12 independently of each other are unsubstituted or substituted phenyl; X is CO or a direct bond; R13 is for example C1-C20alkyl which optionally is substituted, C2-C12alkenyl, C4- C8cycloalkenyl, C2-C12alkinyl, C3-C10cycloalkyl, phenyl or naphthyl both of which are optionally substituted; R14 is for example hydrogen, C3-C8cycloalkyl, C2-C5alkenyl, C1-C20alkoxy, C1-C20alkyl, phenyl or naphthyl; R15 is for example C6-C20aryl or C5-C20heteroaryl; R16 is for example C6-C20aryl which is unsubstituted or substituted by one or more C1-C20alkoxy or C1-C20alkyl; are in particular suitable as photoinitiators for color filter applications.

  式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7和R8例如彼此独立地为氢、C1-C20烷基、(II)、COR16或NO2，前提是至少有一对R1和R2、R2和R3、R3和R4、R5和R6、R6和R7或R7和R8为(III)；R9、R10、R11和R12例如彼此独立地为氢、C1-C20烷基，可以选择地取代；或者R9、R10、R11和R12彼此独立地为未取代或取代的苯基；X为CO或直接键；R13例如为C1-C20烷基，可以选择地取代，C2-C12烯基，C4-C8环烯基，C2-C12炔基，C3-C10环烷基，苯基或萘基，两者均可以选择地取代；R14例如为氢、C3-C8环烷基、C2-C5烯基、C1-C20烷氧基、C1-C20烷基、苯基或萘基；R15例如为C6-C20芳基或C5-C20杂芳基；R16例如为未取代或取代的C6-C20芳基，其取代基为一个或多个C1-C20烷氧基或C1-C20烷基；特别适用于彩色滤光片应用的光引发剂。
• Fe(III) chloride catalyzed conversion of epoxides to acetonides
  作者：Sumit Saha、Samir Kumar Mandal、Subhas Chandra Roy

  DOI：10.1016/j.tetlet.2008.07.147

  日期：2008.10

  A mild and efficient method for the preparation of acetonides from epoxides catalyzed by iron(III) chlorides has been developed.

  已经开发了一种温和而有效的方法，用于从氯化铁（III）催化的环氧化物制备乙炔化物。
• TETRACYCLIC COMPOUNDS
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP2975024A1

  公开（公告）日：2016-01-20

  A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).

  下式（I）所代表的化合物或其盐或溶液，可作为 ALK 抑制剂，用于预防或治疗伴随 ALK 异常的疾病，例如癌症、癌症转移、抑郁症或认知功能障碍： (式中所含符号的含义与说明书中给出的相同）。